Case Report
Published on 20 Feb 2023
in Primary Immunodeficiencies
Case Report
Published on 17 Feb 2023
in Primary Immunodeficiencies
Hypothesis and Theory
Published on 17 Feb 2023
in Primary Immunodeficiencies
Case Report
Published on 16 Feb 2023
in Primary Immunodeficiencies
Case Report
Published on 13 Feb 2023
in Primary Immunodeficiencies
Original Research
Published on 08 Feb 2023
in Primary Immunodeficiencies
Original Research
Published on 07 Feb 2023
in Primary Immunodeficiencies
Original Research
Published on 02 Feb 2023
in Primary Immunodeficiencies
Review
Published on 23 Jan 2023
in Primary Immunodeficiencies
Review
Published on 23 Jan 2023
in Primary Immunodeficiencies
Original Research
Published on 20 Jan 2023
in Primary Immunodeficiencies
Original Research
Published on 13 Jan 2023
in Primary Immunodeficiencies
Case Report
Published on 12 Jan 2023
in Primary Immunodeficiencies
Editorial
Published on 10 Jan 2023
in Primary Immunodeficiencies
Original Research
Published on 10 Jan 2023
in Primary Immunodeficiencies
Original Research
Published on 09 Jan 2023
in Primary Immunodeficiencies
Original Research
Published on 06 Jan 2023
in Primary Immunodeficiencies
Review
Published on 04 Jan 2023
in Primary Immunodeficiencies
Original Research
Published on 04 Jan 2023
in Primary Immunodeficiencies
Case Report
Published on 04 Jan 2023
in Primary Immunodeficiencies
Case Report
Published on 27 Dec 2022
in Primary Immunodeficiencies
Correction
Published on 20 Dec 2022
in Primary Immunodeficiencies
Original Research
Published on 16 Dec 2022
in Primary Immunodeficiencies
Original Research
Published on 14 Dec 2022
in Primary Immunodeficiencies
![Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies](https://www.frontiersin.org/files/myhome article library/1110388/1110388_Thumb_400.jpg)
